Last reviewed · How we verify
POMA — Competitive Intelligence Brief
marketed
Protein cereblon, Cereblon isoform 4
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
POMA (POMA) — Bristol. Poma is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| POMA TARGET | POMA | Bristol | marketed | Protein cereblon, Cereblon isoform 4 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). POMA — Competitive Intelligence Brief. https://druglandscape.com/ci/poma. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab